Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Exploratory analysis finds beneficial effect on patient outcomes at one year, according to a study presented at ACC.24.

News | Cardiovascular Clinical Studies

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the ...

April 06, 2024

The Minneapolis Heart Institute Foundation (MHIF) is presenting data on trends in ST-elevation myocardial infarction (STEMI) at the American College of Cardiology’s Annual Scientific Session (ACC.24). An analysis of nearly 8,000 STEMI patients over 20 years found the majority of STEMI occur in individuals without prior cardiovascular disease.

News | ACC

Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends ...

April 06, 2024

Registration is open for a leading conference on structural heart disease announced by the Cardiovascular Research Foundation, CRF.

News | Cardiovascular Business

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

April 5, 2024 — The Cardiovascular Research Foundation (CRF) has announced New York Valves: The Structural Heart Summit ...

April 05, 2024

Cardiawave SA will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia

News | Cardiovascular Ultrasound

Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

April 05, 2024

Early coronary disease and impaired heart function, with increased coronary vessel wall thickness, in asymptomatic, middle-aged individuals living with HIV has been reported in a new study published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

News | Population Health

New Study Finds Early Coronary Disease, Impaired Heart Function in Asymptomatic People with HIV

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

April 04, 2024

Study shows women quickly catch up to men in terms of cardiovascular risk

News | Womens Cardiovascular Health

Heart Health Declines Rapidly After Menopause

April 2, 2024 — A woman’s cardiovascular risk can rise sharply after she goes through menopause, quickly catching up to ...

April 02, 2024

Study finds patients on average consume more than twice the recommended daily amount of sodium with little variation across socioeconomic groups

News | Womens Cardiovascular Health

Majority of People with Heart Disease Consume Too Much Sodium

April 2, 2024 — Individuals with heart disease stand to gain the most from a low sodium diet but, on average, consume ...

April 02, 2024

Large study adds to growing body of evidence that vaping may harm the heart

News | Heart Failure

Study Links E-Cigarette Use with Higher Risk of Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

April 02, 2024

News | FDA

U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new ...

April 01, 2024

Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number

News | Heart Valve Technology

New Technology Promises to Revolutionize Valvular Heart Disease Care

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

April 01, 2024

Analysis signals higher risk of hypertension among females resting less than seven hours compared with males, according to data to be presented at the upcoming American College of Cardiology Annual Scientific Session & Expo, ACC.24, to be held April 6-8 in Atlanta, GA.

News | Hypertension

Getting Too Little Sleep Linked to High Blood Pressure

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

April 01, 2024

While likelihood of cardiomyopathy grows over time, the overall risk remains low

News | Pediatric Cardiology

ADHD Stimulants May Increase Risk of Heart Damage in Young Adults

March 29, 2024 — Young adults who were prescribed stimulant medications for attention-deficit/hyperactivity disorder (AD ...

March 29, 2024

V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at ACC24

News | Heart Failure

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

March 29, 2024

Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE Platform among U.S. patients

News | Atrial Fibrillation

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

March 28, 2024

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

News | FDA

FDA Approves Merck’s WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

March 27, 2024 — Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug ...

March 27, 2024